- Home
- CTNT vs MREO Comparison
CTNT vs MREO Comparison
Compare CTNT & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTNT | MREO |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 52.5M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CTNT | MREO |
|---|---|---|
| Price | $3.26 | $0.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 168.1M | 1.6M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.74 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,288,536.00 | $500,000.00 |
| Revenue This Year | $42.49 | $5,184.20 |
| Revenue Next Year | $22.22 | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 182.69 | N/A |
| 52 Week Low | $0.02 | $0.20 |
| 52 Week High | $4.21 | $2.94 |
Technical Indicators
Market Signals| Indicator | CTNT | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 75.48 | 28.72 |
| Support Level | $1.48 | $0.20 |
| Resistance Level | N/A | $0.36 |
| Average True Range (ATR) | 0.36 | 0.03 |
| MACD | 0.28 | -0.00 |
| Stochastic Oscillator | 72.54 | 17.58 |
Price Performance
Historical ComparisonAbout CTNT Cheetah Net Supply Chain Service Inc.
Cheetah Net Supply Chain Service Inc is a provider of logistics and warehousing services, historically in connection with the sale of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, and more recently for the transportation of other goods between the U.S. and the PRC. Parallel-import vehicles in the PRC refer to automobiles purchased directly from overseas markets and imported for sale outside of the brand manufacturer's official distribution networks. The company operates as single report segment. The company operates in the USA and overseas.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).